Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study was to systematically collect data on safety and tolerability of krill powder in humans and simultaneously gain efficacy data by measuring the risk factors for cardiovascular disease.
The study was a randomised, double-blinded, placebo-controlled intervention study with slightly obese subjects with mildly or moderately elevated blood pressure. Study was conducted at two study sites in Central (Tampere) and Northern Finland (Oulu). In total 35 subjects were randomised according to randomisation list to two groups (krill powder or placebo) in a balanced manner (1:1), separately for both gender and site. Concealed allocation was used to keep both subjects and staff blinded. The study consisted of a pre-screening, Day -7-(-14) screening visit, Day 0 baseline (Randomization visit) and 8-week safety and tolerance follow-up period with three follow-up visits on Day 14, Day 28 and Day 56.
As a primary endpoint of the study, the total number of reported adverse events were compared in the study subject groups taking 8 capsules (4 g) krill oil powder or 8 capsules (4 g) of placebo for the 8-week follow-up period.
Krill powder is a food supplement rich in active ingredients such as fatty acids, phospholipids, protein and antioxidants like astaxanthin. It is considered to be more effective in lowering triglyceride values than fish oils and it may have positive effect on cholesterol values as well. Krill proteins may have positive effect on blood pressure and astaxanthin has anti-oxidative and anti-inflammatory properties. Thus, krill powder has a lot of potential in improving lipid values and having other positive health effects on cardiovascular system. However, there haven't been many clinical studies done with krill powder and thus systematic data on human safety is limited.
The aim of this study was to systematically collect data on safety and tolerability of krill powder in humans and simultaneously gain efficacy data by measuring the risk factors for cardiovascular disease.
The study was a randomised, double-blinded, placebo-controlled intervention study with slightly obese subjects with mildly or moderately elevated blood pressure. Study was conducted at two study sites in Central (Tampere) and Northern Finland (Oulu). In total 35 subjects were randomised according to randomisation list to two groups (krill powder or placebo) in a balanced manner (1:1), separately for both gender and site. Concealed allocation was used to keep both subjects and staff blinded. The study consisted of a pre-screening, Day -7-(-14) screening visit, Day 0 baseline (Randomization visit) and 8-week safety and tolerance follow-up period with three follow-up visits on Day 14, Day 28 and Day 56.
A total of 6 study visits were included. At pre-screening visit the study subjects were requested to sign pre-screening visit informed consent form. A structured interview on demographics (age, sex, ethnicity), previous and current diseases, current medication, alcohol and tobacco consumption and use of dietary supplements (especially fish oil and other n-3 fatty acid (FA) supplements, plant sterols and cholesterol lowering fiber supplements (guar gum, glucomannan, oat fiber etc.) and use of fish foods was carried out at the screening visit and replicated at the day 56 visit. Study included one test product: krill powder derived from antarctic krill (Euphausia Superba) (Rimfrost Pristine®, Rimfrost AS, PO box 234, 6099 Fosnavaag, Norway) and placebo product and both were given in capsule form, 4 capsules in the morning and 4 in the evening.
Nutritional counselling regarding the consumption of fish, omega-3 and -6 fatty acids, food supplements and investigational product for the duration of the study were given for the study subjects at the screening visit by a study nurse or registered dietitian and compliance was followed throughout the study. The subjects were advised to keep their medication, lifestyle, background diet and body weight constant during the study and deviation were recorded into the diary.
As a primary endpoint of the study, the total number of reported adverse events were compared in the study subject groups taking 8 capsules (4 g) krill oil powder or 8 capsules (4 g) of placebo for the 8-week follow-up period. Any unfavourable and unintended sign, symptom or medical complaint and worsening of a pre-existing condition was regarded as adverse event (AE). Study subjects kept diary for the whole duration of the study and were requested to write down all unfavourable symptoms and medical complaints not existing at baseline or significantly worsened from baseline situation. Completeness of diaries was checked at each study visit. All reported adverse events were recorded, coded and analysed carefully to determine severity, possible relation to study products, onset and outcome of the event. In addition, safety laboratory values, cholesterol and triglyceride values and blood pressure was measured.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Krill oil | Active Comparator | Krill powder capsules, 4 g |
|
| Placebo | Placebo Comparator | Placebo capsules, maize strach, 4 g |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nutritional counseling A | Dietary Supplement | Krill powder capsules |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Adverse events | Total number of reported adverse events | Screening, baseline, day 28, day 56 |
| Measure | Description | Time Frame |
|---|---|---|
| Type of adverse event | Coding by MedDRA and reported with System organ class (SOC) and Prefered term (PT) levels, seriousness, severity, onset and causality of the reported adverse events | Screening, baseline, day 28, day 56 |
| Change in Systolic blood pressure |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Oy Medfiles Ltd | Kuopio | 70701 | Finland |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30572894 | Derived | Sarkkinen ES, Savolainen MJ, Taurio J, Marvola T, Bruheim I. Prospective, randomized, double-blinded, placebo-controlled study on safety and tolerability of the krill powder product in overweight subjects with moderately elevated blood pressure. Lipids Health Dis. 2018 Dec 20;17(1):287. doi: 10.1186/s12944-018-0935-x. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D064420 | Drug-Related Side Effects and Adverse Reactions |
| ID | Term |
|---|---|
| D064419 | Chemically-Induced Disorders |
Not provided
Not provided
two parallel groups (placebo and Krill oil), intervention trial (56 days)
Not provided
Not provided
Not provided
| Nutritional counselling B |
| Dietary Supplement |
Placebo capsules |
|
Mean and mean change (0 vs 8 wk) in systolic blood pressure recorded with 1 mmHg accuracy taken in the screening and during the intervention visits (three measurements are taken altogether and an average of last two measures is used in the analysis) |
| Screening, baseline, day 28, day 56 |
| Change in Diastolic blood pressure | Mean and mean change (0 vs 8 wk) in diastolic blood pressure recorded with 1 mmHg accuracy taken in the screening and during the intervention visits (three measurements are taken altogether and an average of last two measures is used in the analysis) | Screening, baseline, day 28, day 56 |
| Change in thyrotropin | Regular safety parameters from the blood including mean and median variables of blood thyrotropin | Screening, baseline, day 28, day 56 |
| Change in Alanine transaminase (ALT) | Regular safety parameters from the blood including mean and median variables of blood Alanine transaminase (ALAT) | Screening, baseline, day 28, day 56 |
| Change in Aspartate transaminase (AST) | Regular safety parameters from the blood including mean and median variables of blood Aspartate transaminase (ASAT) | Screening, baseline, day 28, day 56 |
| Change in blood glucose | Regular safety parameters from the blood including mean and median variables of blood glucose | Screening, baseline, day 28, day 56 |
| Change in gamma glutamyl transferase | Regular safety parameters from the blood including mean and median variables of gamma glutamyl transferase | Screening, baseline, day 28, day 56 |
| Change in creatinine | Regular safety parameters from the blood including mean and median variables of creatinine | Screening, baseline, day 28, day 56 |
| Change in blood count | Regular safety parameters from the blood including mean and median variables of blood count | Screening, baseline, day 28, day 56 |
| Change in Thyroid stimulating hormone (TSH) | Regular safety parameters from the blood including mean and median variables of Thyroid stimulating hormone (TSH) | Screening, baseline, day 28, day 56 |
| Change in Triglycerides | Mean concentration of serum total triglycerides and mean change (0 vs 8 wk) in serum total and lipoprotein lipids | Screening, baseline, day 28, day 56 |
| Change in total cholesterol | Mean concentration of total cholesterol during the 8-week intervention and mean change (0 vs 8 wk) in serum total and lipoprotein lipids | Screening, baseline, day 28, day 56 |
| Change in Low density lipoproteine (LDL)-cholesterol | Mean concentration of serum LDL-cholesterol during the 8-week intervention and mean change (0 vs 8 wk) in serum total and lipoprotein lipids | Screening, baseline, day 28, day 56 |
| Change in High density lipoproteine (HDL)-cholesterol | Mean concentration of serum HDL-cholesterol during the 8-week intervention and mean change (0 vs 8 wk) in serum total and lipoprotein lipids | Screening, baseline, day 28, day 56 |